Scarica l'app Stockscreener
2.36
0.83%
0.04
Precedente Chiudi:
$2.40
Aprire:
$2.4
Volume 24 ore:
9,493
Relative Volume:
0.01
Capitalizzazione di mercato:
$427.44M
Reddito:
$109.16M
Utile/perdita netta:
$-107.78M
Rapporto P/E:
-2.1332
EPS:
-1.1063
Flusso di cassa netto:
$-95.45M
1 W Prestazione:
-1.22%
1M Prestazione:
+13.62%
6M Prestazione:
+86.15%
1 anno Prestazione:
+339.92%
Intervallo 1D:
$2.37
$2.415
Intervallo di 1 settimana:
$2.285
$2.50
Portata 52W:
$0.435
$3.04
Century Therapeutics Inc Stock (IPSC) Company Profile
Nome
Century Therapeutics Inc
Settore
Industria
Telefono
215-981-4000
Indirizzo
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
2.37 | 441.87M | 109.16M | -107.78M | -95.45M | -1.1063 |
VRTX
Vertex Pharmaceuticals Inc
|
515.11 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
662.07 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
924.51 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
316.50 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.78 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-25 | Iniziato | TD Cowen | Buy |
| 2024-08-08 | Iniziato | Rodman & Renshaw | Buy |
| 2023-08-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-12-27 | Iniziato | Chardan Capital Markets | Buy |
| 2022-10-31 | Iniziato | Guggenheim | Buy |
| 2022-10-10 | Iniziato | Canaccord Genuity | Buy |
| 2022-05-23 | Iniziato | H.C. Wainwright | Buy |
| 2022-05-12 | Iniziato | William Blair | Mkt Perform |
| 2021-07-13 | Iniziato | BofA Securities | Buy |
| 2021-07-13 | Iniziato | JP Morgan | Overweight |
| 2021-07-13 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Century Therapeutics Inc Borsa (IPSC) Ultime notizie
Century Therapeutics, Inc.(NasdaqCM: IPSC) added to Russell 2000 Index - marketscreener.com
Century Therapeutics, Inc.(NasdaqCM: IPSC) added to Russell 2000 Value Benchmark - marketscreener.com
Century Therapeutics, Inc.(NasdaqCM:IPSC) added to Russell Microcap Value Benchmark Index - marketscreener.com
Century Therapeutics, Inc.(NasdaqCM: IPSC) added to Russell Microcap Index - marketscreener.com
Century Therapeutics, Inc. Actuals & Estimates (NASDAQ:IPSC) - TradingView
Enterprise value to EBIT forward of Century Therapeutics, Inc. – NASDAQ:IPSC - TradingView
Price to earnings forward of Century Therapeutics, Inc. – NASDAQ:IPSC - TradingView
IPSC Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Century Therapeutics, Inc. – NASDAQ:IPSC - TradingView
Century Therapeutics updates its CAR-T pipeline, shares trade on Nasdaq - AD HOC NEWS
Century Therapeutics Inc (IPSC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight - GlobeNewswire Inc.
Century Therapeutics Inc (IPSC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Century Therapeutics Inc (IPSC) Institutional Confidence - TradingKey
Century Therapeutics Inc (IPSC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Century Therapeutics Inc (IPSC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Century Therapeutics Inc (IPSC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Century Therapeutics Inc (IPSC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Century Therapeutics Inc (IPSC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Century Therapeutics Inc (IPSC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Century Therapeutics amends chief scientific officer contract to part-time role By Investing.com - Investing.com South Africa
Century Therapeutics amends chief scientific officer contract to part-time role - Investing.com India
Century retains Chad Cowan as part-time Chief Scientific Officer with reduced pay - TradingView
Century Therapeutics (IPSC) shifts Chief Scientific Officer to part-time role with new pay terms - Stock Titan
Century Therapeutics SVP Carr sells $3,691 in company stock By Investing.com - Investing.com India
Century Therapeutics SVP Carr sells $3,691 in company stock - Investing.com
Century Therapeutics executive Gregory Russotti sells $5,767 in stock By Investing.com - Investing.com Nigeria
Century Therapeutics executive Gregory Russotti sells $5,767 in stock - Investing.com
Century Therapeutics (IPSC) executive sells shares to cover RSU tax withholding - Stock Titan
Tax-related share sale by Century Therapeutics (IPSC) SVP Carr - Stock Titan
Century Therapeutics (IPSC) CEO reports 13,849-share tax withholding on RSU vesting - Stock Titan
Century Therapeutics (IPSC) CSO reports tax withholding of shares and restated holdings - Stock Titan
Century Therapeutics Shareholders Approve Directors and Share Increase - The Globe and Mail
Here's Why We're Watching Century Therapeutics' (NASDAQ:IPSC) Cash Burn Situation - Yahoo Finance
Century Therapeutics (IPSC) director Alessandro Riva granted 74,000 stock options - Stock Titan
Director Daphne Quimi receives 74,000 stock options at Century Therapeutics (NASDAQ: IPSC) - Stock Titan
Century Therapeutics (IPSC) director receives grant of 74,000 stock options - Stock Titan
Century Therapeutics (IPSC) director granted 74,000 stock options at $2.24 - Stock Titan
Century Therapeutics (IPSC) awards 74,000 stock options to director Kimberly Blackwell - Stock Titan
Century Therapeutics (IPSC) shareholders back higher authorized shares and board slate - Stock Titan
Insider sale notice for IPSC (NASDAQ: IPSC) — 2,584 shares planned; prior disposals listed - Stock Titan
Century Therapeutics (IPSC) Reports Positive Preclinical Results For Diabetes Cell Therapy CNTY-813 - Insider Monkey
10 Hot Biotech Stocks Under $5 to Buy - Insider Monkey
Mizuho Securities Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Century Therapeutics (IPSC) executive logs small automatic share sale for taxes - Stock Titan
Century Therapeutics (IPSC) SVP’s automatic 249-share sale covers RSU tax withholding - Stock Titan
Century Therapeutics (NASDAQ: IPSC) CEO has 463 shares withheld for RSU taxes - Stock Titan
Century Therapeutics, Inc. (IPSC) Presents at American Diabetes Association (ADA) 86th Scientific SessionsSlideshow (NASDAQ:IPSC) 2026-06-09 - Seeking Alpha
Century Therapeutics, Inc. (IPSC) Stock Price, News, Quote & History - Yahoo! Finance Canada
Century Therapeutics Advances CNTY-813 Diabetes Cell Therapy - TipRanks
Century Therapeutics presents preclinical data on diabetes therapy By Investing.com - Investing.com South Africa
Century Therapeutics Inc Azioni (IPSC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Century Therapeutics Inc Azioni (IPSC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Carr Douglas | SVP Finance & Operations |
Jun 12 '26 |
Sale |
2.23 |
1,654 |
3,692 |
505,094 |
1.95%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):